可切除局部晚期ALK重排非小细胞肺癌的新辅助克唑替尼治疗
本文描述11例经病理确诊为N2的ALK阳性NSCLC初治患者,接受新辅助克唑替尼250 mg每日两次治疗。10例获部分缓解、1例疾病稳定,10例(91.0%)实现R0切除,2例达病理完全缓解;1例出现4级肝损伤。作者认为新辅助克唑替尼可能可行且耐受良好,但需前瞻性试验验证。
要点
- 11例ALK阳性N2 NSCLC初治患者接受新辅助克唑替尼250 mg每日两次。
- 10例(91.0%)实现R0切除,2例达病理完全缓解,1例出现4级肝损伤。
- 作者认为新辅助克唑替尼可能可行且耐受良好,但需前瞻性试验验证疗效。
核心结论
- 作者认为新辅助克唑替尼在局部晚期可完全切除的疾病中可能可行且耐受良好,但需正在进行的前瞻性试验验证其在新辅助 setting 中的疗效。
研究设计与样本
- 本文描述11例经病理确诊为N2的ALK受体酪氨酸激酶基因(ALK)阳性NSCLC患者,均接受新辅助克唑替尼治疗。
- 所有患者均为初治,克唑替尼起始剂量为250 mg每日两次。
- 患者3在新辅助治疗前后通过血浆和组织二代测序进行动态监测;病例4进行了术前组织二代测序。
主要发现
- 11例患者中,新辅助克唑替尼后10例达部分缓解、1例为疾病稳定,1例出现4级肝损伤。
- 11例患者中10例(91.0%)接受R0切除,2例对新辅助克唑替尼达病理完全缓解。
- 6例患者出现疾病复发,其中5例接受克唑替尼作为一线治疗并获得长持续时间缓解。
- 患者3的血浆和组织同时动态监测提示敏感ALK信号降低和部分缓解(约为部分缓解的50%),未捕获ALK依赖性耐药变异。
关键数值与推荐
- 克唑替尼起始剂量为250 mg每日两次。
- 11例中10例(91.0%)接受R0切除。
- 11例中2例达病理完全缓解。
- 11例中1例出现4级肝损伤。
临床怎么用
- 作者认为新辅助克唑替尼在局部晚期疾病中对于完全切除可能可行且耐受良好。
- 作者认为术前克唑替尼治疗可能彻底清除循环分子残留病且不影响一线克唑替尼的再次使用。
- 作者指出需正在进行的前瞻性试验验证其在新辅助 setting 中的疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Locally advanced NSCLC is one of the most heterogeneous conditions, with multidimensional treatments involved. Neoadjuvant therapy had been commonly considered an optimal management strategy for patients with operable locally advanced. However, as targeted therapy has been widely applied in advanced NSCLC, neoadjuvant targeted therapy has remained poorly explored in locally advanced disease. METHODS: We have described 11 ALK receptor tyrosine kinase gene (ALK)-positive patients with pathologically confirmed N2 NSCLC who were treated with neoadjuvant crizotinib. All the patients were treatment naive and received crizotinib at a starting dose of 250 mg twice daily. Patient 3 was provided with dynamic monitoring before and after neoadjuvant therapy through next-generation sequencing of plasma and tissue. In case 4, next-generation sequencing of preoperative tissue was performed. RESULTS: Of the 11 patients, 10 had a partial response and one was stable disease after neoadjuvant crizotinib, with one suffering from grade 4 hepatic damage. Of the 11 patients, 10 (91.0%) received an R0 resection and 2 patients achieved a pathological complete response to neoadjuvant crizotinib. Six patients had disease recurrence, with five of them receiving crizotinib as first-line treatment and achieving a long duration of response. Dynamic monitoring of both plasma and tissue simultaneously indicated a decrease in sensitive ALK signaling in patient 3 and a partial response (approximately 50% of partial response), and no ALK-dependent resistance variants were captured. CONCLUSION: Neoadjuvant crizotinib may be feasible and well tolerated in locally advanced disease for complete resection. Crizotinib therapy before surgery may provide thorough elimination of circulating molecular residual disease and not influence the reuse of first-line crizotinib, but ongoing prospective trials are warranted to prove its efficacy in the neoadjuvant setting.
引用
- Zhang C, Li SL, Nie Q, et al. Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement. J Thorac Oncol. 2018. PMID: 30408570. doi:10.1016/j.jtho.2018.10.161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。